Biomedicines, Volume 12, Issue 6 (June 2024) – 244 articles
Cover Story (view full-size image):
Accurate diagnosis of Alzheimer’s disease (AD) and Frontotemporal dementia (FTD) represents a health issue due to the absence of disease traits. Biomarkers have gained a pivotal role in clinical trials, as they accurately reflect the underlying pathology in pre- or oligosymptomatic stages of different dementias. Cerebrospinal fluid (CSF) SIMOA biomarkers exhibit increased levels in AD and FTD samples compared to controls. Moreover, novel statistical models based on a combination of different biomarkers and demographics and clinical patients’ characteristics classify the dimensional clinical datasets into confident disease clusters, highlighting the need for more representative samples, variables, and measurements for successful and more efficient cohort clustering. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Previous Issue
Next Issue
